gvtcx

Licence variation: spironolactone for acne in women

NHS England Published 17 Jan 2025 Contracts Finder

key details

Value£171,500
Statusunsuccessful
Category (CPV) 85100000 +1 more
RegionYorkshire and the Humber
Deadline7 Oct 2024
Procedureopen
OCIDocds-h6vhtk-045808

Award

SupplierValueDateStatus
not named · · unsuccessful

description

NHS England required a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

9 notices published against this procurement.

PublishedTypeRegimeNotice
8 May 2024 Prior information notice (F01) Earlier regulations 014716-2024
19 Jun 2024 Contract notice (F02) Earlier regulations 018965-2024
19 Jun 2024 Tender (tender) · 72425a04-ec46-4213-a43e-dced693982c4-760737
26 Jun 2024 Tender (tender) · adc04648-0f09-40e8-a396-e4ff61afca06-762309
2 Jul 2024 Corrigendum (F14) Earlier regulations 020184-2024
5 Sept 2024 Contract notice (F02) Earlier regulations 028524-2024
5 Sept 2024 Tender (tender) · 95d29f1d-739e-49bb-94a8-f3a69aacea0e-783269
2 Oct 2024 Corrigendum (F14) Earlier regulations 031592-2024
17 Jan 2025 Contract award notice (F03) Earlier regulations 001753-2025

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.